Page last updated: 2024-09-03

iguratimod and Pulmonary Fibrosis

iguratimod has been researched along with Pulmonary Fibrosis in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Han, X; Li, Q; Liu, W; Sun, L; Wang, J1
Cui, Y; Dong, G; Lin, H; Wu, C; Xie, Y; Zhang, G; Zhang, X; Zhu, F1
Li, D; Liang, Y; Qu, Z; Shao, S; Xu, Y; Yin, S; Zhang, Y; Zhou, D1
Cheng, Y; Huang, C; Mu, B; Zhao, L; Zhou, R1

Other Studies

4 other study(ies) available for iguratimod and Pulmonary Fibrosis

ArticleYear
Iguratimod ameliorates bleomycin-induced pulmonary fibrosis by inhibiting the EMT process and NLRP3 inflammasome activation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Topics: Animals; Bleomycin; Chromones; Epithelial-Mesenchymal Transition; Inflammasomes; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Pulmonary Fibrosis; Reactive Oxygen Species; Sulfonamides

2022
Anti-fibrotic effect of iguratimod on pulmonary fibrosis by inhibiting the fibroblast-to-myofibroblast transition.
    Advances in medical sciences, 2020, Volume: 65, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Bleomycin; Cell Movement; Cell Proliferation; Cells, Cultured; Chromones; Fibroblasts; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Pulmonary Fibrosis; Sulfonamides

2020
Iguratimod decreases bleomycin-induced pulmonary fibrosis in association with inhibition of TNF-α in mice.
    International immunopharmacology, 2021, Volume: 99

    Topics: A549 Cells; Actins; Animals; Bleomycin; Cadherins; Chromones; Collagen; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Matrix Metalloproteinase 2; Mice; NF-kappa B; Pneumonia; Pulmonary Fibrosis; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vimentin

2021
Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9.
    International journal of rheumatic diseases, 2019, Volume: 22, Issue:4

    Topics: Airway Remodeling; Animals; Anti-Inflammatory Agents; Bleomycin; Chromones; Collagen; Cytokines; Disease Models, Animal; Inflammation Mediators; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice, Inbred C57BL; Pneumonia; Pulmonary Alveoli; Pulmonary Fibrosis; Sulfonamides

2019